Therefore, the identified small-molecule agents may reverse the over-expression levels of two hub genes (COL14A1, SFRP4) and two TFs (BNC2, MEOX2) in HF, thus inhibiting the regulatory network of TFs–hub genes–pathways and then alleviating HF progression. The gene discussed is BNC2; the disease is hydrops fetalis.